DOCSLIB.ORG

Meeting of the Trust Board Friday 23 May 2014 AGENDA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meeting of the Trust Board Friday 23 May 2014 AGENDA Meeting of the Trust Board Friday 23rd May 2014 Dear Members There will be a public meeting of the Trust Board on Friday 23rd May 2014 at 3:00pm in York House Conference Room, Great Ormond Street, London, WC1N 3JH. Company Secretary Direct Line: 020 7813 8230 Fax: 020 7813 8218 AGENDA Agenda Item Presented by Author STANDARD ITEMS 1. Apologies for absence Chairman Verbal Declarations of Interest All members are reminded that if they have any pecuniary interest, direct or indirect, in any contract, proposed or other matter which is the subject of consideration at this meeting, they must disclose that fact and not take part in the consideration or discussion of the contract, proposed contract or other matter, nor vote on any questions with respect to it. 2. Minutes of Meeting held on 27th March 2014 Chairman J 3. Matters Arising/ Action Checklist Chairman K 4. Interim Chief Executive Report Chief Executive Verbal ANNUAL ACCOUNTS 5. NHS Foundation Trust Final Accounts and Annual Audit Committee L Report 2013-14 including Chair/ Chief Finance Officer/ Company Annual Governance Statement Secretary Code of Governance Head of Internal Audit Opinion 6. Quality Report 2013-14 Co-Medical Director M 7. Annual Report of Audit Committee 2013-14 Chief Finance N Officer STRATEGIC ISSUES 8. Extended Working Update Director of Planning O and Information 9. Outpatient Improvement Project Director of Planning Presentation and Information & Campbell McKerracher, COO Meridian Productivity 10. Update on Referrer work Co-Medical Director Q (CC) 11. Productivity and Efficiency – the new programme Chief Operating Presentation Officer PERFORMANCE 12. Performance Report Chief Executive S Quality and Safety Co-Medical Director Targets and Indicators Chief Operating Officer Director of Human Workforce Resources &OD Chief Finance Finance Officer Patient Experience Chief Nurse 13. Safe Nurse Staffing Report Chief Nurse T 14. IPSOS Mori inpatient survey Chief Nurse U 15. Safeguarding Annual Report 2013-14 Chief Nurse V 16. Education Annual Report 2013-2014 Director of Human W Resources &OD GOVERNANCE 17. Compliance with the NHS provider licence Company Secretary X 18. Schedule of Matters reserved for the Board and Company Secretary 7 – to follow Members’ Council and Responsibilities of the Chairman and Chief Executive 19. Annual Risk Report 2013-14 Co-Medical Director Y 20. Update on CQC registration Company Secretary Z 21. Register of Seals Company Secretary 1 REPORTS FROM COMMITTEES 22. Audit Committee update – April 2014 meeting Chair of the Audit 2 Committee 23. Clinical Governance Committee update – April Chair of the Clinical 3 2014 meeting Governance Committee 24. Board of Directors Remuneration Committee Chair of the BoD 4 update – March 2014 Remuneration Committee & Chair Board of Directors Nominations Committee of the BoD update – March 2014 Nominations Committee 25. Finance and Investment Committee Update – April Chair of the Finance 5 2014 and Investment Committee 26. Members’ Council Update – April 2014 Chairman of the 6 Members’ Council Any Other Business (Please note that matters to be raised under any other business should be notified to the Company Secretary before the start of the Board meeting.) Next meeting The next Trust Board meeting will be held on Wednesday 24th July 2014 in York House, Great Ormond Street, London, WC1N 3JH. ATTACHMENT J Attachment J DRAFT Minutes of the meeting of Trust Board on 27th March 2014 Present Baroness Tessa Blackstone Chairman Mr Julian Nettel Interim Chief Executive Ms Mary MacLeod Non-Executive Director Ms Yvonne Brown* Non-Executive Director Mr John Ripley Non-Executive Director Mr David Lomas Non-Executive Director Mr Charles Tilley Non-Executive Director Mr Robert Burns Director of Planning and Information Professor Martin Elliott Co-Medical Director Mrs Liz Morgan Chief Nurse and Families’ Champion Mrs Claire Newton Chief Finance Officer Mr Ali Mohammed Director of Human Resources and OD In attendance Mr Robert Burns Director of Planning and Information Mr Matthew Tulley Director of Redevelopment Dr Anna Ferrant Company Secretary Ms Victoria Goddard Trust Board Administrator (minutes) Dr John Harley* Director of Infection, Prevention and Control (DIPC) 6 members of the public *Denotes a person who was present for part of the meeting 158. Apologies for absence 158.1 Apologies were received from Dr Catherine Cale, Interim Co-Medical Director and Professor Ros Smyth, Non-Executive Director. 159. Declarations of interest 159.1 No declarations of interest were received. 160. Minutes from the meeting on 20th January 2014 160.1 The minutes from the previous meeting were approved. 161. Matters arising/action checklist 161.1 The actions which had been taken were noted. 162. Interim Chief Executive Report 162.1 Mr Julian Nettel, Interim Chief Executive provided an update on the following items: Trust Board strategy day which took place on 26th February. ‘Our Commitment’ consultation which started in January and has seen over 1000 questionnaires returned from patients and families. 27th March 2014 Great Ormond Street Hospital for Children NHS Foundation Trust –Trust Board DRAFT 1 minutes Attachment J Launch of the ICH strategy in March ‘Duties of candour’ announced by the Secretary of State following the Francis Report, Professor Martin Elliott, Co-Medical Director taking the lead on how this will be embedded at GOSH. Media attention about potential newborn organ donation Visit to GOSH by Archbishop Desmond Tutu who visited Koala and Bear Wards. Offsted inspection which rated the Hospital School outstanding. 162.2 The Board noted the update. 163. Quality Strategy 163.1 Professor Martin Elliott, Co-Medical Director reported that the updated strategy had amended standard 4 and added a standard 11 around the need to improve standardisation in processes. He said that the format was likely to change later in the year but the content would remain the same. 163.2 Mr Nettel stressed that it was vital to translate the document into a format that all staff could implement in their roles and which would become embedded across the organisation. 163.3 Mrs Mary MacLeod, Non-Executive Director suggested that in order to improve the flow through ICU, training was required across the specialties around giving children with a long stay in intensive care overly burdensome treatment where the likelihood of success is very small. She stressed that a Board level discussion needed to take place. Mrs MacLeod added that Clinical Ethics consults had proved valuable, particularly in cases where there was disagreement between clinicians on a way forward. 163.4 Mr John Ripley, Non-Executive Director asked how the people strategy would support the implementation of the quality strategy. 163.5 Professor Elliott confirmed that recruitment would be based on the quality strategy and added that processes and procedures would be developed in each area for each standard. 163.6 The Board approved the Quality strategy and stressed that it must be implemented through a robust communications strategy. 164. Trust 2 year operational plan 164.1 Mr Robert Burns, Director of Planning and Information reported that the operational plan would be amended following feedback from the Finance and Investment Committee meeting. He added that the financial plan had also been considered by the committee. 164.2 Mr David Lomas, Non-Executive Director and Chair of the Finance and Investment Committee said that the committee had expressed some concern that costs were projected to grow faster than revenue and it had been agreed that the Executive Team would consider where there could be moderation of costs to a more sustainable level. He confirmed that the plan had been endorsed subject to this amendment. 27th March 2014 Great Ormond Street Hospital for Children NHS Foundation Trust –Trust Board DRAFT 2 minutes Attachment J 164.3 Action: It was agreed that the reference to being the top ranked children’s hospital in Europe would be removed and GOSH would continue to benchmark itself against North American institutions. 164.4 The Board commended the comprehensive plan and thanked Alex Faulkes, former Head of Planning and Performance for his work. 164.5 The Board approved the plan subject to the above amendments. 165. Information Management and Technology – direction of travel 165.1 Ms Rachel Williams, Chief Operating Officer reported that it was vital to ensure that changes were clinically led and that learning was gathered from other Trusts. 165.2 The Board stressed the importance of strong change management skills in an IMT programme director and of recognising the project as one of technology underpinning transformation. 165.3 The Board approved the direction of travel and supported rapid progress. 166. Performance Report 166.1 Quality and Safety 166.2 Professor Martin Elliott reported that there had been no significant change in the mortality rate or CVL infections which remained constant. He added that he was pleased to see the reduction in the number of arrests outside ICU which was as a result of the success of the deteriorating child programme. 166.3 Professor Elliott highlighted the significant improvement shown by Rheumatology in the timely completion of discharge summaries. 166.4 Patient Experience 166.5 Mrs Liz Morgan, Chief Nurse and Families’ Champion confirmed that the Trust was, from 1st April 2014, part of the Friends and Family test for inpatients. 166.6 Action: It was agreed that the draft results of the IPSOS Mori inpatient survey would be reported to the Trust Board in May. Mrs Morgan added that an additional, national, children’s inpatient survey would take place later in the year which would enable benchmarking. Ms Yvonne Brown left the meeting. 166.7 Targets and Indicators 166.8 Ms Rachel Williams, Chief Operating Officer reported that work was on-going around access to the Intensive Care Unit (ICU). 166.9 Baroness Blackstone, Chairman queried the reason for the continued poor performance in the timeliness of discharge summaries.
Load more

Recommended publications
  • Uclpartners Academic Health Science Partnership
    UCLPartners academic health science partnership Professor the Lord Ajay Kakkar, Chair, UCLPartners Professor Sir David Fish, Managing Director, UCLPartners Dr Charlie Davie, Director of UCLPartners AHSN Clare Panniker, Chief Executive, Basildon and Thurrock University Hospitals NHS Foundation Trust What is UCLPartners? Six million population 23 healthcare organisations acute and 11 higher education institutes mental health trusts; community providers and research networks 20 Clinical Commissioning Groups (CCGs) Industry partnerships in research and 26 boroughs and local councils translation of innovation into health and wealth 2 Local Enterprise Partnership – key challenge • Working with the London Enterprise Panel, established by the Mayor of London • Professor Stephen Caddick, Vice Provost (Enterprise), UCL, is the only academic representative on the Panel • Key challenges of the panel: to compete with Boston and San Francisco; improve access to the NHS market to increase venture capital • How UCLPartners is contributing: working with industry to co-create technology and devices; creating long-term partnerships with industry and giving confidence to entrepreneurs, e.g. through new business models and procurement initiatives • Other areas of joint working: MedCity, Care City, London Health Commission, three London AHSNs and preparing to enable the success of the Francis Crick Institute 3 Defragmenting the pathway – an integrated journey to transform healthcare through innovation into practice Bringing together formal designations under
    [Show full text]
  • Applying Polygenic Risk Scoring for Psychiatric Disorders to a Large
    http://www.diva-portal.org This is the published version of a paper published in . Citation for the original published paper (version of record): de Jong, S., Abdalla Diniz, M J., Saloma, A., Gadelha, A., Santoro, M L. et al. (2018) Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder Communications Biology, 1: 163 https://doi.org/10.1038/s42003-018-0155-y Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-157800 ARTICLE DOI: 10.1038/s42003-018-0155-y OPEN Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder Simone de Jong1,2, Mateus Jose Abdalla Diniz3,4, Andiara Saloma3,4, Ary Gadelha3, Marcos L. Santoro5, 1234567890():,; Vanessa K. Ota3,5, Cristiano Noto3, Major Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium#, Charles Curtis1,2, Stephen J. Newhouse2,6,7, Hamel Patel2,6, Lynsey S. Hall8, Paul F. O`Reilly1, Sintia I. Belangero3,5, Rodrigo A. Bressan3 & Gerome Breen 1,2 Psychiatric disorders are thought to have a complex genetic pathology consisting of interplay of common and rare variation. Traditionally, pedigrees are used to shed light on the latter only, while here we discuss the application of polygenic risk scores to also highlight patterns of common genetic risk. We analyze polygenic risk scores for psychiatric disorders in a large pedigree (n ~ 260) in which 30% of family members suffer from major depressive disorder or bipolar disorder.
    [Show full text]
  • Clinical Academic Leadership in COVID-19: a Rapid Leader: First Published As 10.1136/Leader-2020-000292 on 1 July 2020
    Brief report Clinical academic leadership in COVID-19: a rapid leader: first published as 10.1136/leader-2020-000292 on 1 July 2020. Downloaded from response to sharing emerging insights in intensive care Nirandeep Rehill,1,2 Amanda Begley,1 Katie Mantell,1 C Michael Roberts1 1UCL Partners, London, UK ABSTRACT assume that role. UCLPartners is a partnership of 2 NIHR Applied Health Research Background The COVID-19 pandemic has raised a 23 National Health Service (NHS) trusts and 9 North Thames, London, UK wide range of challenges for health systems around the higher education institutions covering north central world and the National Health Service in England has and east London and parts of Essex, Hertfordshire Correspondence to Dr Amanda Begley, UCL been no exception. A significant proportion of infected and Bedfordshire. Governed by a partnership board Partners, London W1T 7HA, UK; cases require intensive care unit support and have a high and led by clinical academics supported by a corpo- amanda. begley@ uclpartners. mortality rate. In the early stages of the pandemic, there rate senior team, its purpose is to bring together com was neither an evidence base nor a clinical consensus on organisations to work collaboratively for the health and care of the population served. Received 18 May 2020 the optimal management of patients in this setting. Revised 9 June 2020 Interventions Responding to requests for assistance Accepted 11 June 2020 to address this evidence gap, UCLPartners, an Academic SHARING EMERGING INSIGHTS Health Science Partnership, working in collaboration with Through our partnership, we received intelligence other organisations including National Institute of Health that clinicians were concerned that the traditional Research Applied Research Collaboration North Thames, management of ARDS and other complications was developed a clinical academic team to synthesise clinical not having expected outcomes against this novel learning in real time.
    [Show full text]
  • Dr Charlie Davie, Managing Director, Uclpartners
    Collaborating with industry and researchers to deliver improved healthcare Dr Charlie Davie, Managing Director, UCLPartners UCLPartners – a partnership organisation Parts of London, Bedfordshire, Hertfordshire and Essex 6 million 46 11 population Healthcare Higher education organisations and partners clinical commissioners 844 100s 6 primary care practices industry partnerships Sustainability and Transformation Partnerships A unique business model UCLPartners aligns the following functions in one partnership: • Academic Health Science Centre (AHSC) • Academic Health Science Network (AHSN) • NIHR Collaboration for Applied Health Research and Care (CLAHRC/ARC) • Commercial Trials Prime Site • NIHR Clinical Research Network (CRN) • Genomic Medicine Centre 5 Life Sciences Industrial Strategy • Science: Continued support for the science base, maintaining strength and international competitiveness. • Growth: An environment that encourages companies to start and grow, building on strengths across the UK, including expansion of manufacturing in the sector. • NHS: NHS and industry collaboration, facilitating better care for patients through better adoption of innovative treatments and technologies. • Data: Making the best use of data and digital tools to support research and better patient care. • Skills: Ensuring that the sector has access to a pool of talented people to support its aims through a strong skills strategy. 6 7 The Accelerated Access Review Aim: To speed up access to innovation and grow the UK life sciences industry Recommendations in five key areas: 1. Patients, clinicians and charities to be the key drivers in innovation 2. A new accelerated access pathway will prioritise innovations 3. Open and transparent pathways to bring forward medtech, digital and diagnostics 4. Driving innovation through NHS planning, increasing capacity, clinical leadership and incentives 5.
    [Show full text]
  • Health Tech Innovator Drdoctor Gains Three New NHS Contracts
    Press release Health tech innovator DrDoctor gains three new NHS contracts Patient appointment innovator DrDoctor is working with three new major NHS Trusts: • A major children’s hospital, where the system is being configured in record time and will manage the Trust’s 150000 specialist outpatient appointments • Whittington Health NHS Trust, covering all appointments across the Trust • University Hospital Southampton NHS Foundation Trust, DrDoctor is piloting in Paediatrics to demonstrate an estimated 30% DNA rate reduction DrDoctor supports hospitals with digital transformation. Its system allows patients to view, change and schedule outpatient appointments themselves, online, on smartphone or by conversational SMS. DrDoctor chief executive Tom Whicher said: “We are thrilled to support three more forward thinking Trusts in their journey to provide effective, digital first, patient centric services. All three implementations will deliver, in year cash savings, increase patient satisfaction and form a strong foundation for future digital transformation.” DrDoctor reduces the number of missed and unscheduled appointments and allows patients to opt in to receiving paperless communications, releasing print and postage savings to Trusts. New analysis at Guy’s and St Thomas’ NHS Foundation Trust has revealed that in one year the Trust has saved £2.2m, and patient satisfaction is 96 percent. DrDoctor is supporting a major London children’s hospital’s strategic plan to become the leading paediatric centre in the world. DrDoctor was engaged in January 2017 to deploy its Appointment Management Platform. DrDoctor’s platform is a fundamental shift away from an inconsistent approach to appointment management. The platform will go-live in the summer of 2017.
    [Show full text]
  • Developing the Evidence Base for London's Local Industrial Strategy
    Developing the evidence base for London’s Local Industrial Strategy - Interim report August 2019 Developing the evidence base for London’s Local Industrial Strategy - Interim report copyright Greater London Authority August 2019 Published by Greater London Authority City Hall The Queens Walk London SE1 2AA www.london.gov.uk Tel 020 7983 4000 Minicom 020 7983 4000 ISBN 978-1-84781-719-8 Cover photograph © Shutterstock For more information about this publication, please contact: GLA Economics Tel 020 7983 4000 Email [email protected] GLA Economics provides expert advice and analysis on London’s economy and the economic issues facing the capital. Data and analysis from GLA Economics form a basis for the policy and investment decisions facing the Mayor of London and the GLA group. GLA Economics uses a wide range of information and data sourced from third party suppliers within its analysis and reports. GLA Economics cannot be held responsible for the accuracy or timeliness of this information and data. The GLA will not be liable for any losses suffered or liabilities incurred by a party as a result of that party relying in any way on the information contained in this report. Acknowledgements GLA Economics would like to thank all colleagues at the GLA and in other organisations who contributed to this report, including: • Members of the Analytical Working Group, especially the ONS regional statisticians (Sukriti Verma and Tom Liu) for all their work on developing London-relevant statistics; • Gerard Burgess and Jorn Peters in the GLA Planning Directorate for their very valuable comments and contributions to Chapters 7 and 8; • Professor Stephen Roper at the Enterprise Research Centre (Warwick Business School) for his valuable advice on Chapter 6; • The LIS Evidence Base Independent Expert Panel – Professor Riccardo Crescenzi, Dr.
    [Show full text]
  • Self-Care in Young People with Diabetes: a Qualitative Exploration Using a Salutogenic Approach
    SELF-CARE IN YOUNG PEOPLE WITH DIABETES: A QUALITATIVE EXPLORATION USING A SALUTOGENIC APPROACH EMMA GREEN A thesis submitted in partial fulfilment of the requirements of the University of East London for the degree of Doctor of Philosophy September 2018 Abstract This thesis investigates experiences of self-care amongst young people with diabetes using a qualitative salutogenic approach. Diabetes self-care includes injecting insulin, counting carbohydrates, attending hospital check-ups and other activities to maintain stable blood sugar levels. Optimal blood sugar levels are not always easy for young people with diabetes to attain, placing them at increased risk of health complications. A lack of self-care has been assumed traditionally to indicate a lack of knowledge. This exemplifies a ‘deficit’ approach whereby efforts to improve self-care focus heavily on diabetes education to increase knowledge. However, there is a lack of evidence that young people lack diabetes knowledge or that education-only interventions are effective. This thesis applies salutogenesis as an alternative to the deficit approach in which young people are conceptualised as individuals and their capabilities are acknowledged. The empirical work undertaken includes: a meta-ethnography of the international qualitative literature, analysis of semi-structured interviews with young people living in a diverse urban area of the UK, defined as disengaged from diabetes self-care (N=14): and a qualitative study conducted with young people participating in novel salutogenic projects which focused on their capabilities rather than ‘correcting’ their deficits (N=5). Across the studies it was found that ‘identity work’ underpins young people’s experiences with diabetes self-care.
    [Show full text]
  • Physical and Mental Health
    Physical and mental health Health and Wellbeing Innovation Commission Inquiry Health and care Carers Care homes Social care Culture and society Community Retirement Infrastructure Retirement housing November 2018 Physical and mental health: health and wellbeing commission 1 Contents 1. Introduction 10 2. Setting the scene 11 3. Innovations in prevention and early daignosis 18 4. Innovations in self-management 29 5. Innovations in primary care 35 6. Innovations in secondary care 42 7. Barriers and opportunities 51 8. Recommendations 60 This report outlines key findings from a Health and Wellbeing Commission Enquiry, conducted by ILC, supported by EY and Audley. This report is one of four reports drawing together findings from evidence sessions held by the Commission during 2018. In our mental and physical health session we examined the potential for innovations which directly impact mental and physical health. We found there are significant gains to be made by increasing the rate of development, incubation and spread of innovation in this area. Sally Bowell Sally joined the International Longevity Centre as a Research Fellow in May 2017. Her work at the think tank has focused predominantly on health & social care, looking at topics such as music- based interventions for people with dementia, ageism in the breast cancer care pathway, and innovation in physical and mental health. 2 Physical and mental health: health and wellbeing commission Executive summary The benefits of innovation include improved quality of care, enhanced patient outcomes, and cost efficiencies. However, there are challenges to realising the potential of innovation in this area – and particularly in relation to moving from development to roll out and scaling.
    [Show full text]
  • Histology Research Scientist (International Brain Laboratory) Information for Candidates
    Histology Research Scientist (International Brain Laboratory) Information for Candidates Sainsbury Wellcome Centre for Neural Circuits and Behaviour at UCL CONTENTS Job Description………………………………………………………………………….……………………………3 About the International Brain Laboratory ........................................................................................... 3 About the Sainsbury Wellcome Centre .............................................................................................. 3 Background, Mission and Research Environment ............................................................................. 3 The Role of Histology Research Scientist (IBL) ................................................................................. 4 Main Duties and Responsibilities ...................................................................................................... 4 Selection Criteria ........................................................................................................................................ 6 Contact Us .................................................................................................................................................. 7 How to Apply .............................................................................................................................................. 7 Terms of Appointment ............................................................................................................................... 8 The Neuroscience Environment at UCL ...................................................................................................
    [Show full text]
  • Board of Directors Part One
    Board of Directors Part One Agenda and papers of a meeting to be held 2pm – 3pm Tuesday 31st January 2012 Board Room, Tavistock Centre, 120 Belsize Lane, London, NW3 5BA Board of Directors 2pm – 3pm, Tuesday 31st January 2012 Agenda Preliminaries 1. Chair’s Opening Remarks Ms Angela Greatley, Trust Chair 2. Apologies for Absence 3. Minutes of the Previous Meeting (Minutes attached) For approval 4. Matters Arising Reports & Finance 5. Trust Chair’s and Non-Executive Directors’ Reports For noting Non-Executive Directors as appropriate 6. Chief Executive’s Report (Report attached) Dr Matthew Patrick, Chief Executive For discussion 7. Finance & Performance (Report attached) Mr Simon Young, Director of Finance For discussion 8. Quarterly Declarations (Declarations attached) MrSimonYoung,DirectorofFinance Forapproval Ms Louise Lyon, Trust Director Quality & Development 9. UCLP Mental Health & Wellbeing Programme (Report attached) Prof. Peter Fonagy, Chair, UCLP For discussion Prof. Alessandra Lemma, T&P Psychological Therapies Development Unit Lead 10.RiO 2015 Outline Business Case (Report attached) Mr Allan Archibald, Head of Informatics For approval Conclusion 11.Any other business 12.Notice of future meetings Thursday 2nd February 2012 : Board of Governors Tuesday 28th February 2012 : Board of Directors Wednesday 14th March 2012 : Directors Conference Tuesday 27th March 2012 : Board of Directors Tuesday 24th April 2012 : Board of Directors Tuesday 29th May 2012 : Board of Directors Wednesday 13th June 2012 : Directors Conference Thursday
    [Show full text]
  • A Digital Health Hub Welcome
    A Digital Health Hub Welcome Medical science and innovation is at the heart of modern least for joining the design and supply of technology with civilisation, and is the cornerstone of modern healthcare. the demands of transforming healthcare and delivering We find ourselves in an era of scientific convergence, better outcomes for patients and the clinicians who care Contents where different disciplines are coming together to shape for them, but also to underpin the system effectiveness the way that care is provided with increasing focus on and sustainability necessary to produce those improved The digital health opportunity 4 personalised and true precision medicine. The digital and outcomes. “omic” revolutions which are advancing hand in hand have the potential to transform both public health, and the way The UK government is leading the way in this field with Why you need to be in the 6 we deliver healthcare and more effective disease digital health a strategic priority for the NHS. The “golden golden triangle treatment modalities in an holistic sense to individual triangle” encompassed by Cambridge, London, and patients. Oxford provides a unique life sciences and technology ecosystem which promotes the growth and adoption of An ideal place to conduct clinical trials 8 Digital technologies are empowering people across the digital health technologies. breadth of society to track and manage their own health Snapshot of the ecosystem whilst also enabling the healthcare industry to efficiently Together we invite our colleagues from across the globe for digital health 10 manage, access and analyse all the available data. to collaborate with industry and academia within the region to help drive forward future health innovations and The National Health Service: Discoveries however are not made in isolation.
    [Show full text]
  • The Effectiveness of Anti-Corruption Policy
    Systematic review The effectiveness of anti-corruption policy What has worked, what hasn’t, and what we don’t know by Professor Rema Hanna Sarah Bishop Sara Nadel Gabe Scheffler Katherine Durlacher July 2011 The EPPI-Centre reference number for this report is 1909. This report should be cited as: Hanna, R., Bishop, S., Nadel, S., Scheffler, G, Durlacher, K. (2011) The effectiveness of anti-corruption policy: what has worked, what hasn‟t, and what we don‟t know–a systematic review. Technical report. London: EPPI-Centre, Social Science Research Unit, Institute of Education, University of London. ISBN: 978-1-907345-14-2 © Copyright Authors of the systematic reviews on the EPPI-Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI-Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission. The effectiveness of anti-corruption policy i Contents List of abbreviations .......................................................................... iii Structured abstract ............................................................................ 1 Executive summary ............................................................................ 2 1. Background .................................................................................. 7 1.1 Aims and rationale for review .......................................................
    [Show full text]